HCM HUTCHMED Ltd: Forward P/S Multiple

Corporate emblem and logo of Hutchison MediPharma (HCM)

HUTCHMED (HCM) balances the risks of developing new oncology drugs through stable pharmaceutical distribution in the PRC. The forward P/S trend on the GURU.Markets chart demonstrates market expectations, where the 1.00 mark serves as a key metric. High-tech proprietary plants ensure operational stability, while strict temperature control during the air transport of innovative agents guarantees delivery reliability.

HCM (Hutchison MediPharma) Market Cap to Future Revenue Ratio history from 07/04/2022 to 11/15/2026

Analytical breakdowns for HUTCHMED (China) Limited (HCM)

- market price and analyst price targets:
Price Chart hutch-med.com|HCM - Average Forecast Price
- company stock capitalization data:
Market Capitalization HUTCHMED (China) Limited|HCM - Full Takeover Company Value
- issuer book value statistics:
Accounting Value per Share HUTCHMED|HCM - Total Stockholders' Equity|Market Cap to Net Assets Ratio hutch-med.com|HCM - Aggregate Asset Value
- debt and liquidity details:
Total Debt to Equity Ratio HUTCHMED (China) Limited|HCM - Long-Term Loans to Capital Ratio|Short-Term Debt to Capital HUTCHMED|HCM - Aggregate Debt Obligations|Debts to Book Capitalization HUTCHMED Corp|HCM - Long-Term Debt|Company Short-Term Debt HUTCHMED|Quick Ratio hutch-med.com
- net income and valuation multiples indicators:
HCM - Net Profit|Expected Profit HUTCHMED (China) Limited|HCM - Market Cap to Net Income|Projected Price to Earnings Hutchison MediPharma|HCM - Price to Earnings Adjusted for Growth Rate|EV/EBITDA Multiple Hutchison MediPharma|HCM - Income before deduction of interest, taxes and amortization|Net earnings per share for the last 12 months HUTCHMED|HCM - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months hutch-med.com|HCM - Net earnings per one share growth for the current year|Earnings growth forecast for next year HUTCHMED (China) Limited
- revenue and sales details:
HCM - Company Sales|Projected Sales Volume HUTCHMED Ltd|HCM - Market Capitalization-to-Revenue Ratio|Price-to-Projected Revenue Ratio Hutchison MediPharma|HCM - Revenue Growth YoY (Last 12 Months)
Summary company analysis:hutch-med.com HCM
Manufactured products of HUTCHMED Corp

As a knowledge-intensive oncology therapy ecosystem with a globally expanding patient base, HUTCHMED (HCM) is valued by the market through the ratio of current market capitalization to projected annual revenue. By analyzing the forward P/S ratio, an investor determines the value of each dollar of expected sales, which allows them to strip away market illusions and assess the actual pace of share revaluation against the backdrop of stringent FDA and NMPA regulatory filters.

Competitor analysis

Price-to-Projected Revenue Ratio Incyte Corp. INCY|Nuvation Corp - Price-to-Projected Revenue Ratio|DAWN - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Monopar Therapeutics|INBX: Forward P/S Multiple|Projected Price to Revenue I-Mab IMAB|Forward Price-to-Revenue Multiple FENC|Market Cap to Future Revenue Ratio Heron Therapeutics, Inc. HRTX|Forward Price-to-Revenue Multiple NVCT (Nuvectis Pharma, Inc.)|CHRS (Coherus BioSciences) - Forward Price to Sales|Corbus Pharmaceuticals - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio CRDF (Cardiff Oncology Corp)|BeyondSpring Pharma - Forward P/S Multiple|Forward Price to Sales BCAB (bioatla.com)|LIXT: Forward P/S Multiple|Market Cap to Future Revenue Ratio Citius Pharma (CTXR)|Price-to-Projected Revenue Ratio Cellectar Biosciences, Inc.|BLRX: Forward Price to Sales|Forward P/S Multiple CANF|Forward P/S Multiple Aprea Therapeutics Inc. (APRE)|Price-to-Projected Revenue Ratio Kazia Therapeutics Ltd KZIA|SLXN (silexion.com) - Future Price to Revenue|NCNA: Forward Price-to-Revenue Multiple|Market Cap to Future Revenue Ratio Chimerix|CYCC: Forward P/S Multiple|Projected Price to Revenue G1 Therapeutics Inc. GTHX|Price-to-Projected Revenue Ratio Kronos Bio, Inc.|kintara.com (KTRA) - Market Cap to Expected Sales Ratio|Forward P/S Multiple ONCT|PRTG (Portage) - Forward Price to Sales